Poster Presentation The Pancreas Summit 2025

ABO blood type and the long-term outcomes of pancreatic cancer (#43)

Teru Kumagi 1 , Yoshinori Yoshinori Tanaka 2 , Takashi Terao 1 , Taira Kuroda 3 , Tomoyuki Yokota 4 , Nobuaki Azemoto 4 , Yoshiki Imamura 2 , Yoshiyasu Kisaka 2 , Mitsuhito Koizumi 1 , Yoshinori Ohno 5 , Kozue Kanemitsu 3 , Teruki Miyake 1 , Hideki Miyata 3 , Yoichi Hiasa 1
  1. Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan
  2. Gastroenterology, Matsuyama Shimin Hospital, Matsuyama, Ehime, Japan
  3. Department of Gastroenterology, Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan
  4. Center for Liver-Biliary-Pancreatic Diseases, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan
  5. Gastroenterology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan

AIM: The long-term effect of the ABO blood type on the clinical course of patients with pancreatic cancer (PC) is inconclusive. This study aimed to determine whether or not the ABO blood type influences the long-term outcomes of PC in Japanese patients.

METHODS: The medical records of Japanese patients with PC were reviewed. Data, including the age, sex, and outcomes, from the Ehime Pancreato-Cholangiology Study Group were analyzed.

RESULTS: The mean age of the 406 patients was 71.0±10.5 years, and 220 (54.2%) were men. A total of 44.6%, 20.7%, 22.4%, and 12.3% had blood type A, B, O, and AB, respectively. The median survival time (MST) of patients with A alleles was shorter than that of patients with non-A alleles (p=0.048), especially among those who underwent resection (p=0.031). In contrast, no marked difference in the MST was noted among those who underwent chemotherapy and palliative care. Finally, a multivariate analysis confirmed A alleles as an independent factor associated with the long-term outcome of PC (p<0.05 in 2 different models).

CONCLUSION:  The ABO blood type influenced the long-term outcomes of Japanese patients with PC, presum- ably due to its impact on disease onset and tumor behavior.